| . | PVC cohort (N = 820) . | Controls (N = 3069) . | P . | SMD . |
|---|---|---|---|---|
| Age, median (IQR) | 59.0 (45.0–70.0) | 59.0 (45.0–69.0) | 0.590 | 0.018 |
| Men, n (%) | 347 (42.3) | 1249 (40.7) | 0.425 | 0.033 |
| Ischaemic heart disease, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Heart Failure, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Cancer, n (%) | 112 (13.7) | 265 (8.6) | <0.001 | 0.160 |
| Hypertension, n (%) | 173 (21.1) | 398 (13.0) | <0.001 | 0.218 |
| Diabetes, n (%) | 39 (4.8) | 161 (5.2) | 0.635 | 0.022 |
| Cerebrovascular disease, n (%) | 23 (2.8) | 92 (3.0) | 0.862 | 0.011 |
| Hyperlipidaemia, n (%) | 66 (8.0) | 96 (3.1) | <0.001 | 0.215 |
| Atrial Fibrillation, n (%) | 50 (6.1) | 87 (2.8) | <0.001 | 0.158 |
| Beta Blockers, n (%) | 410 (50.0) | 585 (19.1) | <0.001 | 0.688 |
| Anticoagulants and platelet-inhibitors, n (%) | 238 (29.0) | 570 (18.6) | <0.001 | 0.247 |
| Antiarrhythmic drug, class 1, n (%) | 14 (1.7) | 8 (0.3) | <0.001 | 0.147 |
| Antiarrhythmic drug, class 3, n (%) | 11 (1.3) | 1 (0.0) | <0.001 | 0.159 |
| Calcium channel blockers, n (%) | 216 (26.3) | 520 (16.9) | <0.001 | 0.230 |
| Diuretics, n (%) | 311 (37.9) | 865 (28.2) | <0.001 | 0.208 |
| Digitalis, n (%) | 6 (0.7) | 8 (0.3) | 0.094 | 0.067 |
| ACE inhibitors, n (%) | 159 (19.4) | 472 (15.4) | 0.007 | 0.106 |
| Angiotensin receptor blockers, n (%) | 108 (13.2) | 335 (10.9) | 0.081 | 0.069 |
| . | PVC cohort (N = 820) . | Controls (N = 3069) . | P . | SMD . |
|---|---|---|---|---|
| Age, median (IQR) | 59.0 (45.0–70.0) | 59.0 (45.0–69.0) | 0.590 | 0.018 |
| Men, n (%) | 347 (42.3) | 1249 (40.7) | 0.425 | 0.033 |
| Ischaemic heart disease, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Heart Failure, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Cancer, n (%) | 112 (13.7) | 265 (8.6) | <0.001 | 0.160 |
| Hypertension, n (%) | 173 (21.1) | 398 (13.0) | <0.001 | 0.218 |
| Diabetes, n (%) | 39 (4.8) | 161 (5.2) | 0.635 | 0.022 |
| Cerebrovascular disease, n (%) | 23 (2.8) | 92 (3.0) | 0.862 | 0.011 |
| Hyperlipidaemia, n (%) | 66 (8.0) | 96 (3.1) | <0.001 | 0.215 |
| Atrial Fibrillation, n (%) | 50 (6.1) | 87 (2.8) | <0.001 | 0.158 |
| Beta Blockers, n (%) | 410 (50.0) | 585 (19.1) | <0.001 | 0.688 |
| Anticoagulants and platelet-inhibitors, n (%) | 238 (29.0) | 570 (18.6) | <0.001 | 0.247 |
| Antiarrhythmic drug, class 1, n (%) | 14 (1.7) | 8 (0.3) | <0.001 | 0.147 |
| Antiarrhythmic drug, class 3, n (%) | 11 (1.3) | 1 (0.0) | <0.001 | 0.159 |
| Calcium channel blockers, n (%) | 216 (26.3) | 520 (16.9) | <0.001 | 0.230 |
| Diuretics, n (%) | 311 (37.9) | 865 (28.2) | <0.001 | 0.208 |
| Digitalis, n (%) | 6 (0.7) | 8 (0.3) | 0.094 | 0.067 |
| ACE inhibitors, n (%) | 159 (19.4) | 472 (15.4) | 0.007 | 0.106 |
| Angiotensin receptor blockers, n (%) | 108 (13.2) | 335 (10.9) | 0.081 | 0.069 |
| . | PVC cohort (N = 820) . | Controls (N = 3069) . | P . | SMD . |
|---|---|---|---|---|
| Age, median (IQR) | 59.0 (45.0–70.0) | 59.0 (45.0–69.0) | 0.590 | 0.018 |
| Men, n (%) | 347 (42.3) | 1249 (40.7) | 0.425 | 0.033 |
| Ischaemic heart disease, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Heart Failure, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Cancer, n (%) | 112 (13.7) | 265 (8.6) | <0.001 | 0.160 |
| Hypertension, n (%) | 173 (21.1) | 398 (13.0) | <0.001 | 0.218 |
| Diabetes, n (%) | 39 (4.8) | 161 (5.2) | 0.635 | 0.022 |
| Cerebrovascular disease, n (%) | 23 (2.8) | 92 (3.0) | 0.862 | 0.011 |
| Hyperlipidaemia, n (%) | 66 (8.0) | 96 (3.1) | <0.001 | 0.215 |
| Atrial Fibrillation, n (%) | 50 (6.1) | 87 (2.8) | <0.001 | 0.158 |
| Beta Blockers, n (%) | 410 (50.0) | 585 (19.1) | <0.001 | 0.688 |
| Anticoagulants and platelet-inhibitors, n (%) | 238 (29.0) | 570 (18.6) | <0.001 | 0.247 |
| Antiarrhythmic drug, class 1, n (%) | 14 (1.7) | 8 (0.3) | <0.001 | 0.147 |
| Antiarrhythmic drug, class 3, n (%) | 11 (1.3) | 1 (0.0) | <0.001 | 0.159 |
| Calcium channel blockers, n (%) | 216 (26.3) | 520 (16.9) | <0.001 | 0.230 |
| Diuretics, n (%) | 311 (37.9) | 865 (28.2) | <0.001 | 0.208 |
| Digitalis, n (%) | 6 (0.7) | 8 (0.3) | 0.094 | 0.067 |
| ACE inhibitors, n (%) | 159 (19.4) | 472 (15.4) | 0.007 | 0.106 |
| Angiotensin receptor blockers, n (%) | 108 (13.2) | 335 (10.9) | 0.081 | 0.069 |
| . | PVC cohort (N = 820) . | Controls (N = 3069) . | P . | SMD . |
|---|---|---|---|---|
| Age, median (IQR) | 59.0 (45.0–70.0) | 59.0 (45.0–69.0) | 0.590 | 0.018 |
| Men, n (%) | 347 (42.3) | 1249 (40.7) | 0.425 | 0.033 |
| Ischaemic heart disease, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Heart Failure, n (%) | 0 (0.0) | 0 (0.0) | NA | <0.001 |
| Cancer, n (%) | 112 (13.7) | 265 (8.6) | <0.001 | 0.160 |
| Hypertension, n (%) | 173 (21.1) | 398 (13.0) | <0.001 | 0.218 |
| Diabetes, n (%) | 39 (4.8) | 161 (5.2) | 0.635 | 0.022 |
| Cerebrovascular disease, n (%) | 23 (2.8) | 92 (3.0) | 0.862 | 0.011 |
| Hyperlipidaemia, n (%) | 66 (8.0) | 96 (3.1) | <0.001 | 0.215 |
| Atrial Fibrillation, n (%) | 50 (6.1) | 87 (2.8) | <0.001 | 0.158 |
| Beta Blockers, n (%) | 410 (50.0) | 585 (19.1) | <0.001 | 0.688 |
| Anticoagulants and platelet-inhibitors, n (%) | 238 (29.0) | 570 (18.6) | <0.001 | 0.247 |
| Antiarrhythmic drug, class 1, n (%) | 14 (1.7) | 8 (0.3) | <0.001 | 0.147 |
| Antiarrhythmic drug, class 3, n (%) | 11 (1.3) | 1 (0.0) | <0.001 | 0.159 |
| Calcium channel blockers, n (%) | 216 (26.3) | 520 (16.9) | <0.001 | 0.230 |
| Diuretics, n (%) | 311 (37.9) | 865 (28.2) | <0.001 | 0.208 |
| Digitalis, n (%) | 6 (0.7) | 8 (0.3) | 0.094 | 0.067 |
| ACE inhibitors, n (%) | 159 (19.4) | 472 (15.4) | 0.007 | 0.106 |
| Angiotensin receptor blockers, n (%) | 108 (13.2) | 335 (10.9) | 0.081 | 0.069 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
